GAD1 and Parkinson disease: Studies have shown that delivery of GAD-expressible cDNA using the AAV2 vector (AAV2-GAD) results in stable expression of GAD in the brains of patients with PD, thereby significantly improving motor symptoms (LeWitt et al., 2011; Kaplitt et al., 2007).